oxidases

OG-L002 is an effective and selective LSD1 inhibitor (IC50: 20 nM), showing 69- and 36-fold selectivity over MAO-A and MAO-B, respectively.

2-Phenylethylamine hydrochloride (benzeneethanamine hydrochloride) acts as neuromodulator in the central nervous system. It stimulates the release of norepinephrine and dopamine and is metabolized by monoamine oxidases as well as other enzymes.

Bellidifolin (Bellidifoline) has anti-oxidation, hepatoprotective, anti-inflammatory and antitumor actions, it may contribute to the protective effects associated with nerve injury initiated by hypoxia by mechanisms related to inhibition of cell apoptosis independent of the ERK pathway. Bellidifolin shows interesting inhibitory activity of monoamine oxidases (MAO) A, it could be useful for treating type-2 diabetes, likely via the improvement of insulin resistance (IR). Bellidifolin also shows an antifungal effect (MIC values of 50 microg/mL).

ND-011992 is a reversible and selective quinazoline inhibitor targeting quinone reductases and quinol oxidases.ND-011992 inhibits E. coli BL21*Δcyo respiratory complex I. ND-011992 inhibits bo3 oxidase, bd-I oxidases and bd-II oxidases, ND-011992 inhibits E. coli BL21*Δcyo respiratory complex I, bo3 oxidase, bd-I oxidases, and bd-II oxidases with IC50s of 0.12, 2.47, 0.63, and 1.3 μM, respectively.ND-011992 can be used in the study of tuberculosis.

ChEs/MAOs-IN-1 (Compound 4i) is a dual inhibitor of cholinesterases (ChEs) and monoamine oxidases (MAOs). The IC50 values for ChEs/MAOs-IN-1 are 0.048 μM for AChE, 0.89 μM for BChE, 3.58 μM for MAO-A, and 0.095 μM for MAO-B. This compound can be utilized in studies related to neurodegenerative diseases.

JNJ-64326067 is a blood-brain barrier-penetrant ligand for aggregated tau protein with a Ki of 2.4 nM. It selectively binds to aggregated tau protein without interacting with aggregated β-amyloid and exhibits no significant off-target binding to tested receptors, ion channels, transporters, kinases, or monoamine oxidases. JNJ-64326067 is useful for Alzheimer's disease research.

20-HEPE, a metabolite of eicosapentaenoic acid, is formed via ω-oxidation of EPA by cytochrome P450 (CYP) ω-oxidases, including human CYP4F3B. It activates peroxisome proliferator-activated receptor α (PPARα) in COS-7 cells expressing a luciferase reporter at a concentration of 10 μM. 20-HEPE also activates murine transient receptor potential vanilloid receptor 1 (mTRPV1) in vitro but lacks antinociceptive activity in rats.

PXS-4681A is a powerful, specific, and irreversible inhibitor of semicarbazide-sensitive amine oxidase (SSAO; VAP-1), with an oral activity and a Ki value of 37 nM. It exhibits exceptional selectivity towards related amine oxidases, ion channels, and seven-transmembrane domain receptors. Additionally, PXS-4681A demonstrates potent anti-inflammatory properties.

Bizine dihydrochloride is a potent LSD1 inhibitor in vitro, being selective versus monoamine oxidases A/B and the LSD1 homologue, LSD2.

[Sar1, Ile8]-Angiotensin II acetate activates both the NADPH and NADH oxidases, and stimulates superoxide anion formation in vascular smooth muscle cells. [Sar1, Ile8]-Angiotensin II acetate has multiple effects on vascular smooth muscle, including contra

ChEs/MAOs-IN-2 (compound a11) serves as an inhibitor for both cholinesterases and monoamine oxidases, exhibiting IC 50 values of 0.10 µM for MAO-A, 0.20 µM for MAO-B, 0.30 µM for AChE, and 0.40 µM for BChE. This compound shows promise for Alzheimer's disease research [1].

Acacetin 7-O-(6-O-malonylglucoside) is a reversible inhibitor of hMAO-A and hMAO-B (IC₅₀ = 2.34 and 1.87 μM), respectively, and can be used in the study of neurodegenerative diseases.

1-Amino-1-deoxy-β-D-galactose (β-D-Galactosylamine) is a galactose analog utilized as a competitive inhibitor. It facilitates the separation, purification, identification, differentiation, and characterization of β-D-galactosidases and galactose oxidases.

MeSeI exhibits weak inhibitory activity against monoamine oxidases MAO-A and MAO-B, with IC50 values of 198.8 µM. It modulates dopamine receptor D2 (dopamine receptorD2) and norepinephrine receptors α2, β1 (norepinephrine receptor α2, β1), displaying antidepressant-like effects in mice. Additionally, MeSeI is orally active.

ZG-2291 is a selective inhibitor targeting FIH (hypoxia-inducible factor inhibitor) with oral activity. It selectively inhibits FIH by binding to it and inducing a conformational flip in a catalytically crucial tyrosine, without affecting other 2OG oxidases of the JmjC subfamily. ZG-2291 promotes thermogenesis and ameliorates obesity symptoms and metabolic dysfunctions in ob/ob mice. This compound holds promise for research in the field of obesity-related diseases.